

### **OncoGeneDx: Common Cancer Management Panel**

### **PANEL GENE LIST**

APC, ATM, AXIN2, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CHEK2, EPCAM\*, FH, FLCN, HOXB13, MLH1, MSH2, MSH6, MUTYH, NF1, NTHL1, PALB2, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, SCG5/GREM1\*, SDHB, SDHC, SDHD, SMAD4, STK11, TP53, TSC1, TSC2, VHL \*Testing includes sequencing and deletion/duplication analysis for all genes except EPCAM (del/dup only) and SCG5/GREM1 (del/dup only).

### **CLINICAL FEATURES**

Cancer is a common disease affecting approximately 1 in 3 individuals in the U.S.<sup>1</sup> While the majority of cancers are sporadic in nature, some families have hereditary forms of cancer that are associated with increased cancer risks compared with the general population. Approximately 5-10% of cancer cases are thought to be due to a hereditary predisposition. The features of a personal and/or family history of cancer that are suggestive of a hereditary cancer predisposition include: young ages at diagnosis, multiple primary cancers in a single individual, and several relatives affected with the same type of cancer or related cancers spanning multiple generations.

The OncoGeneDx Common Cancer Management Panel includes analysis of 38 cancer-predisposition genes that have expert clinical management guidelines for pathogenic variant carriers. This panel includes genes associated with well-described hereditary syndromes, such as *BRCA1* and *BRCA2* (Hereditary Breast and Ovarian Cancer Syndrome), *MLH1*, *MSH2*, *MSH6*, *PMS2* and *EPCAM* (Lynch Syndrome), as well as other genes that have overlapping phenotypes.

### **INHERITANCE PATTERN**

Most genes on this panel are associated with an autosomal dominant cancer risk with the exception of *MUTYH* and *NTHL1*, which are associated with an autosomal recessive cancer risk. Some of the genes on this panel are also associated with extremely rare conditions when inherited in an autosomal recessive fashion.

### **TEST METHODS**

Genomic DNA is extracted from the submitted specimen. For skin punch biopsies, fibroblasts are cultured and used for DNA extraction. This DNA is enriched for the complete coding regions and splice site junctions of the genes on this panel using a proprietary targeted capture system developed by GeneDx for next generation sequencing with CNV calling (NGS-CNV). For *PTEN* nucleotides c.-700 through c.-1300 in the promoter region, and for *APC*, promoters 1A and 1B are also captured. The enriched targets are simultaneously sequenced with paired-end reads on an Illumina platform. Bi-directional sequence reads are assembled and aligned to reference sequences based on NCBI RefSeq transcripts and human genome build GRCh37/UCSC hg19. After gene specific filtering, data are analyzed to identify sequence variants and most deletions and duplications involving coding exons. Concurrent *MSH2* Exons 1-7 Inversion analysis from NGS data is also performed. For *EPCAM* and *SCG5*, deletion/duplication analysis, but not sequencing, is performed. Alternative sequencing or copy number detection methods are used to analyze or confirm regions with inadequate sequence or copy number data by NGS. Reportable variants include pathogenic variants, likely pathogenic variants and variants of uncertain significance. Likely benign and benign variants, if present, are not routinely reported but are available upon request.

### **CLINICAL SENSITIVITY**

The clinical sensitivity of sequencing and deletion/duplication analysis of the 38 genes included in the OncoGeneDx Common Cancer Management Panel depends in part on the patient's clinical phenotype and family history. In general, the sensitivity is highest for individuals with features suggestive of a hereditary predisposition to cancer as outlined above. DNA sequencing will detect nucleotide substitutions and small insertions and

## GeneDz

deletions, while NGS-CNV analysis, array CGH, or MLPA will detect exon-level deletions and duplications. These methods are expected to be greater than 99% sensitive in detecting pathogenic variants identifiable by sequencing or CNV technology.

Genetic testing using the methods applied at GeneDx is expected to be highly accurate. Normal findings do not rule out the diagnosis of a genetic disorder since some genetic abnormalities may be undetectable by this test. The methods used cannot reliably detect deletions of 20bp to 250bp in size, or insertions of 10bp to 250 bp in size. Sequencing cannot detect low-level mosaicism. The copy number assessment methods used with this test cannot reliably detect mosaicism and cannot identify balanced chromosome aberrations. Rarely, incidental findings of large chromosomal rearrangements outside the gene of interest may be identified. Regions of certain genes have inherent sequence properties (for example: repeat, homology, or pseudogene regions, high GC content, rare polymorphisms) that yield suboptimal data, potentially impairing accuracy of the results. False negatives may also occur in the setting of bone marrow transplantation, recent blood transfusion, or suboptimal DNA quality. In individuals with active or chronic hematologic neoplasms or conditions, there is a possibility that testing may detect an acquired somatic variant, resulting in a false positive result. As the ability to detect genetic variants and naming conventions can differ among laboratories, rare false negative results may occur when no positive control is provided for testing of a specific variant identified at another laboratory. The chance of a false positive or false negative result due to laboratory errors incurred during any phase of testing cannot be completely excluded. Interpretations are made with the assumption that any clinical information provided, including family relationships, are accurate. Consultation with a genetics professional is recommended for interpretation of results.

#### REFERENCES

1. Probability of Developing or Dying of Cancer - Surveillance Research Program. https://surveillance.cancer.gov/devcan/.

2. Suszynska, M. & Kozlowski, P. Summary of BARD1 Mutations and Precise Estimation of Breast and Ovarian Cancer Risks Associated with the Mutations. Genes 11, (2020).

- 3. Shimelis, H. et al. Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing. J. Natl. Cancer Inst. 110, 855–862 (2018).
- 4. Couch, F. J. et al. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. JAMA Oncol. 3, 1190–1196 (2017).
- 5. Slavin, T. P. et al. The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. NPJ Breast Cancer 3, 22 (2017).

6. Alanee, S., Couch, F. & Offit, K. Association of a HOXB13 variant with breast cancer. N. Engl. J. Med. 367, 480–481 (2012).

- 7. Akbari, M. R. et al. Association between germline HOXB13 G84E mutation and risk of prostate cancer. J. Natl. Cancer Inst. 104, 1260–1262 (2012).
- 8. Ewing, C. M. et al. Germline mutations in HOXB13 and prostate-cancer risk. N. Engl. J. Med. 366, 141–149 (2012).

9. Leoz, M. L., Carballal, S., Moreira, L., Ocaña, T. & Balaguer, F. The genetic basis of familial adenomatous polyposis and its implications for clinical practice and risk management. Appl. Clin. Genet. 8, 95–107 (2015).

10. Alkhouri, N., Franciosi, J. P. & Mamula, P. Familial adenomatous polyposis in children and adolescents. J. Pediatr. Gastroenterol. Nutr. 51, 727–732 (2010).

11. Jasperson, K. W. Genetic testing by cancer site: colon (polyposis syndromes). Cancer J. Sudbury Mass 18, 328-333 (2012).

12. Sieber, O. M. et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N. Engl. J. Med. 348, 791–799 (2003). 13. Tavtigian, S. V. et al. Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am. J. Hum. Genet. 85, 427–446

(2009). 14. Byrnes, G. B., Southey, M. C. & Hopper, J. L. Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories? Breast Cancer Res. BCR 10, 208 (2008).

15. Einarsdóttir, K. et al. Effect of ATM, CHEK2 and ERBB2 TAGSNPs and haplotypes on endometrial cancer risk. Hum. Mol. Genet. 16, 154– 164 (2007).

16. Renwick, A. et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat. Genet. 38, 873–875 (2006).

17. Roberts, N. J. et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2, 41-46 (2012).

18. Thompson, D. et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J. Natl. Cancer Inst. 97, 813–822 (2005).

19. Marvin, M. L. et al. AXIN2-associated autosomal dominant ectodermal dysplasia and neoplastic syndrome. Am. J. Med. Genet. A. 155A,

898–902 (2011).

20. Lammi, L. et al. Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am. J. Hum. Genet. 74, 1043–1050 (2004).

21. Rohlin, A. et al. Expanding the genotype-phenotype spectrum in hereditary colorectal cancer by gene panel testing. Fam. Cancer 16, 195–203 (2017).

22. Brosens, L. A. A. et al. Risk of colorectal cancer in juvenile polyposis. Gut 56, 965–967 (2007).

23. Jasperson, K. W., Tuohy, T. M., Neklason, D. W. & Burt, R. W. Hereditary and familial colon cancer. Gastroenterology 138, 2044–2058 (2010).

24. Ford, D. et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 62, 676–689 (1998).

25. Antoniou, A. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72, 1117–1130 (2003).

T: 1 (888) 729-1206 | F: 1 (201) 421-2010 | GeneDx.com 207 Perry Parkway | Gaithersburg, MD 20877 © 2021 GENEDX, INC. ALL RIGHTS RESERVED.

# **Test Information Sheet**

26. Levine, D. A. et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 21, 4222-4227 (2003).

27. Biron-Shental, T., Drucker, L., Altaras, M., Bernheim, J. & Fishman, A. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma. Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol. 32, 1097–1100 (2006)

28. Chen, S. & Parmigiani, G. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 25, 1329–1333 (2007)

29. Claus, E. B., Schildkraut, J. M., Thompson, W. D. & Risch, N. J. The genetic attributable risk of breast and ovarian cancer. Cancer 77, 2318–2324 (1996). 30. Graeser, M. K. et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 27, 5887-5892 (2009).

31. King, M.-C., Marks, J. H., Mandell, J. B., & New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302, 643-646 (2003).

32. Liede, A., Karlan, B. Y. & Narod, S. A. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 22, 735-742 (2004)

33. Pennington, K. P. et al. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. Cancer 119, 332–338 (2013).

34. Risch, H. A. et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J. Natl. Cancer Inst. 98, 1694-1706 (2006).

35. Ramus, S. J. et al. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. J. Natl. Cancer Inst. 107, (2015).

36. Pritchard, C. C. et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N. Engl. J. Med. 375, 443–453 (2016).

37. Ghazwani, Y. et al. Clinical characteristics and genetic subtypes of Fanconi anemia in Saudi patients. Cancer Genet. 209, 171–176 (2016).

38. Fitzgerald, R. C. et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J. Med. Genet. 47, 436-444 (2010).

39. Guilford, P. et al. E-cadherin germline mutations in familial gastric cancer. Nature 392, 402-405 (1998).

40. Kaurah, P. et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 297, 2360-2372 (2007).

41. Petridis, C. et al. Germline CDH1 mutations in bilateral lobular carcinoma in situ. Br. J. Cancer 110, 1053–1057 (2014).

42. Pharoah, P. D., Guilford, P., Caldas, C., & International Gastric Cancer Linkage Consortium. Incidence of gastric cancer and breast cancer in CDH1 (Ecadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 121, 1348-1353 (2001).

43. Schrader, K. A. et al. Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. J. Med. Genet. 48, 64-68 (2011).

44. Brooks-Wilson, A. R. et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J. Med. Genet. 41, 508-517 (2004).

45. Leachman, S. A. et al. Identification, genetic testing, and management of hereditary melanoma. Cancer Metastasis Rev. 36, 77-90 (2017).

46. Goldstein, A. M. et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J. Med. Genet. 44, 99-106 (2007).

47. Kefford, R. F., Newton Bishop, J. A., Bergman, W. & Tucker, M. A. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 17, 3245–3251 (1999).

48. Czajkowski, R., Placek, W., Drewa, G., Czajkowska, A. & Uchańska, G. FAMMM syndrome: pathogenesis and management. Dermatol. Surg. Off. Publ. Am. Soc. Dermatol. Surg. Al 30, 291-296 (2004).

49. Canto, M. I. et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 62, 339-347 (2013).

50. Soura, E., Eliades, P. J., Shannon, K., Stratigos, A. J. & Tsao, H. Hereditary melanoma: Update on syndromes and management: Emerging melanoma cancer complexes and genetic counseling. J. Am. Acad. Dermatol. 74, 411-420; guiz 421-422 (2016).

51. Cybulski, C. et al. CHEK2 is a multiorgan cancer susceptibility gene. Am. J. Hum. Genet. 75, 1131–1135 (2004).

52. Dong, X. et al. Mutations in CHEK2 associated with prostate cancer risk. Am. J. Hum. Genet. 72, 270-280 (2003).

53. Han, F., Guo, C. & Liu, L. The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis. DNA Cell Biol. 32, 329–335 (2013). 54. Kilpivaara, O., Alhopuro, P., Vahteristo, P., Aaltonen, L. A. & Nevanlinna, H. CHEK2 1157T associates with familial and sporadic colorectal cancer. J. Med. Genet. 43, e34 (2006).

55. Liu, C., Wang, Q.-S. & Wang, Y.-J. The CHEK2 I157T variant and colorectal cancer susceptibility: a systematic review and meta-analysis. Asian Pac. J. Cancer Prev. APJCP 13, 2051-2055 (2012).

56. Seppälä, E. H. et al. CHEK2 variants associate with hereditary prostate cancer. Br. J. Cancer 89, 1966–1970 (2003). 57. Suchy, J. et al. CHEK2 mutations and HNPCC-related colorectal cancer. Int. J. Cancer 126, 3005–3009 (2010).

58. Durno, C. A., Holter, S., Sherman, P. M. & Gallinger, S. The gastrointestinal phenotype of germline biallelic mismatch repair gene mutations. Am. J. Gastroenterol. 105, 2449-2456 (2010).

59. Vasen, H. F. et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110, 1020-1027 (1996)

60. Weissman, S. M. et al. Genetic counseling considerations in the evaluation of families for Lynch syndrome--a review. J. Genet. Couns. 20, 5-19 (2011).

61. Wimmer, K. & Kratz, C. P. Constitutional mismatch repair-deficiency syndrome. Haematologica 95, 699–701 (2010).

62. Win, A. K. et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 30, 958-964 (2012).

63. Li-Chang, H. H. et al. Colorectal cancer in a 9-year-old due to combined EPCAM and MSH2 germline mutations: case report of a unique genotype and immunophenotype. J. Clin. Pathol. 66, 631-633 (2013).

64. Smit, D. L. et al. Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis. Clin. Genet. 79, 49-59 (2011).

65. Home - HLRCC Family Alliance, http://hlrccinfo.org/.

66. Coughlin, E. M. et al. Molecular analysis and prenatal diagnosis of human fumarase deficiency. Mol. Genet. Metab. 63, 254–262 (1998).

67. Menko, F. H. et al. Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Fam. Cancer 13, 637-644 (2014).

T: 1 (888) 729-1206 | F: 1 (201) 421-2010 | GeneDx.com 207 Perry Parkway | Gaithersburg, MD 20877 © 2021 GENEDX, INC. ALL RIGHTS RESERVED.

GeneDz

# Test Information Sheet

68. Pithukpakorn, M. & Toro, J. R. Hereditary Leiomyomatosis and Renal Cell Cancer. in GeneReviews(®) (eds. Pagon, R. A. et al.) (University of Washington, Seattle, 1993).

69. Menko, F. H. et al. Birt-Hogg-Dubé syndrome: diagnosis and management. Lancet Oncol. 10, 1199–1206 (2009).

70. Toro, J. R. et al. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. J. Med. Genet. 45, 321–331 (2008).

71. Benusiglio, P. R. et al. Renal cell tumour characteristics in patients with the Birt-Hogg-Dubé cancer susceptibility syndrome: a retrospective, multicentre study. Orphanet J. Rare Dis. 9, 163 (2014).

72. Schmidt, L. S. et al. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am. J. Hum. Genet. 76, 1023–1033 (2005).

73. Toro, J. R. Birt-Hogg-Dubé Syndrome. in GeneReviews(®) (eds. Pagon, R. A. et al.) (University of Washington, Seattle, 1993).

74. Bonadona, V. et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 305, 2304–2310 (2011). 75. Quehenberger, F., Vasen, H. F. A. & van Houwelingen, H. C. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J. Med. Genet. 42, 491–496 (2005).

76. Baglietto, L. et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J. Natl. Cancer Inst. 102, 193–201 (2010).

77. Boparai, K. S. et al. Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYH-associated polyposis. Gastroenterology 135, 2014–2018 (2008).

78. Out, A. A. et al. MUTYH gene variants and breast cancer in a Dutch case–control study. Breast Cancer Res. Treat. 134, 219–227 (2012). 79. Balaguer, F. et al. Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. Clin. Gastroenterol.

Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 5, 379-387 (2007).

80. Barnetson, R. A. et al. Germline mutation prevalence in the base excision repair gene, MYH, in patients with endometrial cancer. Clin. Genet. 72, 551–555 (2007).

81. Cleary, S. P. et al. Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. Gastroenterology 136, 1251–1260 (2009).

82. Croitoru, M. E. et al. Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk. J. Natl. Cancer Inst. 96, 1631– 1634 (2004).

83. Jenkins, M. A. et al. Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol. 15, 312–314 (2006).

84. Lubbe, S. J., Di Bernardo, M. C., Chandler, I. P. & Houlston, R. S. Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 27, 3975–3980 (2009).

85. Santonocito, C. et al. Common genetic variants of MUTYH are not associated with cutaneous malignant melanoma: application of molecular screening by means of high-resolution melting technique in a pilot case-control study. Int. J. Biol. Markers 26, 37–42 (2011).

86. Vogt, S. et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology 137, 1976-1985.e1–10 (2009).

87. Win, A. K. et al. Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer. Int. J. Cancer 129, 2256–2262 (2011). 88. Slavin, T. P. et al. The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. NPJ Breast Cancer 3, 22 (2017).

89. Ferner, R. E. et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J. Med. Genet. 44, 81–88 (2007).

90. Friedman, J. M. Neurofibromatosis 1. in GeneReviews(®) (eds. Pagon, R. A. et al.) (University of Washington, Seattle, 1993).

91. Ferner, R. E. & Gutmann, D. H. Neurofibromatosis type 1 (NF1): diagnosis and management. Handb. Clin. Neurol. 115, 939-955 (2013).

92. Weren, R. D. A. et al. A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nat. Genet. 47, 668–671 (2015).

93. Rivera, B., Castellsagué, E., Bah, I., van Kempen, L. C. & Foulkes, W. D. Biallelic NTHL1 Mutations in a Woman with Multiple Primary Tumors. N. Engl. J. Med. 373, 1985–1986 (2015).

94. Belhadj, S. et al. Delineating the Phenotypic Spectrum of the NTHL1-Associated Polyposis. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 15, 461–462 (2017).

95. Broderick, P. et al. Validation of Recently Proposed Colorectal Cancer Susceptibility Gene Variants in an Analysis of Families and Patients-a Systematic Review. Gastroenterology 152, 75-77.e4 (2017).

96. Rahman, N. et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat. Genet. 39, 165–167 (2007).

97. Erkko, H. et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature 446, 316–319 (2007).

98. Antoniou, A. C. et al. Breast-cancer risk in families with mutations in PALB2. N. Engl. J. Med. 371, 497–506 (2014).

99. Casadei, S. et al. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res. 71,

2222–2229 (2011).

100. Jones, S. et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324, 217 (2009).

101. Slater, E. P. et al. PALB2 mutations in European familial pancreatic cancer families. Clin. Genet. 78, 490-494 (2010).

102. ten Broeke, S. W. et al. Lynch syndrome caused by germline PMS2 mutations: delineating the cancer risk. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 33, 319–325 (2015).

103. Senter, L. et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 135, 419-428 (2008).

104. Palles, C. et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat. Genet. 45, 136–144 (2013).

105. Bellido, F. et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet. Med. Off. J. Am. Coll. Med. Genet. 18, 325–332 (2016).

106. Spier, I. et al. Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. Int. J. Cancer 137, 320–331 (2015).

107. Wimmer, K. et al. A novel germline POLE mutation causes an early onset cancer prone syndrome mimicking constitutional mismatch repair deficiency. Fam. Cancer 16, 67–71 (2017).

108. Pachlopnik Schmid, J. et al. Polymerase ε1 mutation in a human syndrome with facial dysmorphism, immunodeficiency, livedo, and short stature ('FILS syndrome'). J. Exp. Med. 209, 2323–2330 (2012).

109. Nieuwenhuis, M. H. et al. Cancer risk and genotype-phenotype correlations in PTEN hamartoma tumor syndrome. Fam. Cancer 13, 57–63 (2014).

T: 1 (888) 729-1206 | F: 1 (201) 421-2010 | GeneDx.com 207 Perry Parkway | Gaithersburg, MD 20877 © 2021 GENEDX, INC. ALL RIGHTS RESERVED. GeneDz

# **Test Information Sheet**

110. Tan, M.-H. et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 18, 400-407 (2012).

111. Bubien, V. et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J. Med. Genet. 50, 255-263 (2013).

112. Hobert, J. A. & Eng, C. PTEN hamartoma tumor syndrome: an overview. Genet. Med. Off. J. Am. Coll. Med. Genet. 11, 687–694 (2009).

113. Norquist, B. M. et al. Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol. 2, 482-490 (2016).

114. Lilyquist, J. et al. Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls. Gynecol. Oncol. 147, 375-380 (2017).

115. Rashid, M. U., Muhammad, N., Faisal, S., Amin, A. & Hamann, U. Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan. Breast Cancer Res. Treat. 145, 775-784 (2014).

116. Loveday, C. et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat. Genet. 43, 879-882 (2011).

117. Song, H. et al. Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 33, 2901-2907 (2015).

118. Jaeger, E. et al. Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1. Nat. Genet. 44, 699-703 (2012).

119. Rohlin, A. et al. GREM1 and POLE variants in hereditary colorectal cancer syndromes. Genes. Chromosomes Cancer 55, 95–106 (2016).

120. Lieberman, S. et al. Features of Patients With Hereditary Mixed Polyposis Syndrome Caused by Duplication of GREM1 and Implications for Screening and Surveillance. Gastroenterology 152, 1876-1880.e1 (2017). 121. Lenders, J. W. M. et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 1915–1942

(2014).

122. Kirmani, S. & Young, W. F. Hereditary Paraganglioma-Pheochromocytoma Syndromes. in GeneReviews(®) (eds. Pagon, R. A. et al.)

(University of Washington, Seattle, 1993).

123. Neumann, H. P. H. et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292, 943–951 (2004).

124. Welander, J., Söderkvist, P. & Gimm, O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr. Relat. Cancer 18, R253-276 (2011).

125. Niemann, S. & Müller, U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat. Genet. 26, 268–270 (2000).

126. Peczkowska, M. et al. Extra-adrenal and adrenal pheochromocytomas associated with a germline SDHC mutation. Nat. Clin. Pract. Endocrinol. Metab. 4, 111-115 (2008).

127. Miettinen, M. & Lasota, J. Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs) - a review. Int. J. Biochem. Cell Biol. 53. 514-519 (2014).

128. Benn, D. E. et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J. Clin. Endocrinol. Metab. 91, 827-836 (2006). 129. Jackson, C. B. et al. Mutations in SDHD lead to autosomal recessive encephalomyopathy and isolated mitochondrial complex II deficiency. J. Med. Genet. 51, 170-175 (2014)

130. Jasperson, K. & Burt, R. W. The Genetics of Colorectal Cancer. Surg. Oncol. Clin. N. Am. 24, 683–703 (2015).

- 131. Howe, J. R., Mitros, F. A. & Summers, R. W. The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann. Surg. Oncol. 5, 751-
- 756 (1998).

132. Tomlinson, I. P. & Houlston, R. S. Peutz-Jeghers syndrome. J. Med. Genet. 34, 1007–1011 (1997).

133. Hearle, N. et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 12, 3209-3215 (2006)

134. Giardiello, F. M. et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119, 1447–1453 (2000).

135. Hisada, M., Garber, J. E., Fung, C. Y., Fraumeni, J. F. & Li, F. P. Multiple primary cancers in families with Li-Fraumeni syndrome. J. Natl. Cancer Inst. 90, 606-611 (1998).

136. Chompret, A. et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br. J. Cancer 82, 1932–1937 (2000).

137. Gonzalez, K. D. et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 27, 1250-1256 (2009).

138. Olivier, M. et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 63, 6643-6650 (2003).

139. Ruijs, M. W. G. et al. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J. Med. Genet. 47, 421-428 (2010)

140. Krueger, D. A., Northrup, H., & International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr. Neurol. 49, 255–265 (2013)

141. Au, K. S. et al. Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet. Med. Off. J. Am. Coll. Med. Genet. 9, 88-100 (2007).

142. Northrup, H., Krueger, D. A., & International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 linternational Tuberous Sclerosis Complex Consensus Conference. Pediatr. Neurol. 49, 243–254

(2013)143. Frantzen, C., Klasson, T. D., Links, T. P. & Giles, R. H. Von Hippel-Lindau Syndrome. in GeneReviews(®) (eds. Pagon, R. A. et al.) (University of Washington, Seattle, 1993).

144. Lonser, R. R. et al. von Hippel-Lindau disease. Lancet Lond. Engl. 361, 2059-2067 (2003).

145. Maher, E. R., Neumann, H. P. & Richard, S. von Hippel-Lindau disease: a clinical and scientific review. Eur. J. Hum. Genet. EJHG 19, 617-623 (2011).

146. Mannelli, M. et al. Genetics and biology of pheochromocytoma. Exp. Clin. Endocrinol. Diabetes Off. J. Ger. Soc. Endocrinol. Ger. Diabetes Assoc. 115, 160-165 (2007).

GeneDz